Most of what circulates about omega-3 and cholesterol is a single number, and that number has to compress four different lipid markers measured in four different ways. A 2023 meta-analysis of 90 randomised trials with an overall sample of 72,598 participants is a good place to see what happens when you refuse to compress them.
Four markers, four shapes
The analysis used random-effects one-stage cubic spline models, which is the statistical way of asking “what shape is the relationship” without forcing it into a straight line. The answer, in the authors’ own summary: the relationships are non-linear in general and in most subgroups, showing J-shaped curves for LDL and HDL cholesterol.
A J-shaped curve is the shape that produces the classic public confusion. The relationship turns: at low intakes one direction, at higher intakes another. Any headline that quotes “the effect of omega-3 on LDL” without saying where on the curve the intake sat is describing half a curve.
Where the relationship is actually simple
Two of the four markers behave far more cleanly. For triglycerides and for non-HDL cholesterol, the authors found an approximately linear relationship with daily intake — and the effect is more evident in populations with hyperlipidaemia or with overweight or obesity, given medium to high combined intakes.
This is the practically useful half of the meta-analysis, and it is a statement about shape rather than about a headline number: in people whose triglycerides or non-HDL cholesterol are raised, raising intake is associated with a near-straight-line reduction.
The authors are careful about how far that goes. Their conclusion says the triglyceride-lowering effects “might provide supportive evidence” for omega-3 intake to prevent cardiovascular events. Might provide supportive evidence is not the same as a demonstrated event reduction, and the difference matters.
Why this meta-analysis is worth more than a number
The honest summary of 90 trials is not “omega-3 lowers cholesterol by X percent”. It is: the effect depends on which marker you measure, where on the curve the intake sits, and who the participants were. Three qualifiers, each supported by the analysis itself.
That is also why the intake range matters. The paper studies intake as a continuous variable across trials rather than comparing two fixed amounts, which is the right design for the question — and which is also why its results cannot be compressed into a single bullet point without losing the shape.
What these data do not show
They do not show that omega-3 intake prevents cardiovascular events. The trial endpoints here are blood lipids. The authors’ own wording on events is hedged, and no event trial is described in this paper.
They do not give one percentage for “cholesterol”. LDL and HDL describe J-shaped curves; triglycerides and non-HDL are closer to linear. A pooled figure across those four is arithmetically available and practically meaningless.
They do not identify an optimal intake. A linear relationship over the studied range is not the same as “more is always better”, and a J-shaped curve specifically warns against reading the low-intake segment as the high-intake one.
And they do not cover the forms. This analysis is about fatty acid intake as a quantity. Prescription-grade formulations, food sources versus supplements, and any outcome other than blood lipids are separate literatures with separate evidence, and none of them is settled by these ninety trials.
